share_log

Eve & Co Incorporated Financial Results for the Nine Months Ended September 30, 2021

Eve & Co Incorporated Financial Results for the Nine Months Ended September 30, 2021

Eve&Co公司截至2021年9月30日的9個月的財務業績
GlobeNewswire ·  2021/11/26 06:16

Revenues up 222% to $2.5m and 154% to $6.5m for the three and nine month periods over last year

前三個月和前九個月的收入分別增長222%和154%,達到250萬美元和650萬美元

STRATHROY, Ontario, Nov. 25, 2021 (GLOBE NEWSWIRE) -- Eve & Co Incorporated ("Eve & Co", "we", "us" or the "Company") (TSX-V: EVE; OTCQX: EEVVF), is pleased to announce that it had gross revenues of $6.5 million in the first nine months of 2021, successfully surpassing its gross revenues of $3.8 million for the entire 2020 financial year and $2.6 million for the comparative nine month period in 2020.

安大略省斯特拉特羅伊,2021年11月25日(Global Newswire)--伊夫公司(Eve&Co)(多倫多證券交易所股票代碼:EVE;OTCQX:EEVVF)(多倫多證券交易所股票代碼:EVE;OTCQX:EEVVF)高興地宣佈,2021年前9個月的毛收入為650萬美元,成功超過了2020財年全年380萬美元的毛收入和同期的260萬美元。

The Company is also pleased to announce its financial results for the three and nine months ended September 30, 2021 and wishes to highlight the following items;

公司還高興地宣佈截至2021年9月30日的三個月和九個月的財務業績,並希望強調以下事項;

  • During the first three quarters of 2021, the Company completed additional shipments of EU-GMP certified cannabis to its German customers;
  • During the first three quarters of 2021, the Company has increased the number of provinces in which our products are available: from five to eight provinces. Additionally, the Company introduced four new product SKUs into the Canadian cannabis market;
  • During the first three quarters of 2021, the Company has more than doubled their revenue from the comparable 2020 periods. Furthermore, net loss for the three months was $298,000, down from $4.3 million in 2020;
  • 在2021年的前三個季度,該公司完成了向其德國客户額外發運歐盟GMP認證的大麻;
  • 在2021年的前三個季度,公司增加了我們產品的供應省份:從5個省份增加到8個省份。此外,該公司還向加拿大大麻市場推出了四種新產品SKU;
  • 在2021年的前三個季度,該公司的收入比2020年同期翻了一番多。此外,這三個月的淨虧損為29.8萬美元,低於2020年的430萬美元;
  • On July 13, 2021, the Company announced that it had entered into a supply agreement with Adjupharm GmbH ("AP") for the purchase and export to Germany of its dried cannabis flower. Under the initial three-year agreement, AP is expected to order up to 660 kilograms of dried cannabis flower;
  • On July 19, 2021 the Company announced that it had entered into a supply agreement with Cannamedical Pharma® GmbH ("CM") for the purchase and export of medical grade dried cannabis flower to CM who will distribute medical grade cannabis products in Germany;
  • On August 11, 2021, the Company announced that it had successfully completed its largest shipment of cannabis to a customer in Germany with an estimated retail value of $1.8 million;
  • On August 18, 2021, the Company announced that it had entered into a supply agreement with TCann Pty Ltd., Australia ("TCann") for the purchase and export of medical grade dried cannabis flower to TCann who will distribute medical grade cannabis products in Australia;
  • On September 28, 2021, the Company announced the closing of a private placement of 2,777,778 units, with each unit having one common share and ½ common share purchase warrant at a conversion price of $0.25 for gross proceeds of $500,000. This placement is with a multi-national medical cannabis company who will also lease of a portion of the cultivation area in the Company's Strathroy facility; and,
  • On September 30, 2021, the Company announced Jeannette VanderMarel had joined the Board of Directors, replacing Yasir Naqvi. The Board also appointed Kim Arnel as Interim Chief Financial Officer.
  • 2021年7月13日,該公司宣佈已與Adjupharm GmbH(“AP”)簽訂了一項供應協議,購買並出口其幹大麻花至德國。根據最初的三年協議,美聯社預計將訂購多達660公斤的大麻乾花;
  • 2021年7月19日,該公司宣佈,它已與Cannamedical Pharma®GmbH(“CM”)簽訂了一項供應協議,向CM採購和出口醫用級大麻乾花,CM將在德國分銷醫用級大麻產品;
  • 2021年8月11日,該公司宣佈,它已經成功完成了向德國客户運送的最大一批大麻,估計零售價值為180萬美元;
  • 2021年8月18日,本公司宣佈與澳大利亞TCann Pty Ltd.(“TCann”)簽訂供應協議,向TCann採購和出口醫用級大麻乾花,TCann將在澳大利亞分銷醫用級大麻產品;
  • 2021年9月28日,該公司宣佈結束2,777,778股私募,每股擁有1股普通股和1/2普通股認購權證,換股價格為0.25美元,總收益為50萬美元。這一安排與一家跨國醫用大麻公司合作,該公司還將租賃該公司斯特拉特里工廠的部分種植面積;以及,
  • 2021年9月30日,該公司宣佈珍妮特·範德馬雷爾(Jeannette VanderMarel)取代雅西爾·納克維(Yasir Naqvi)加入董事會。董事會還任命金·阿內爾(Kim Arnel)為臨時首席財務官。

"We are very pleased with the success and progress of the Eve & Co team and the sales results of Q3 of the 2021 financial year.  Our focus has been on the emerging and growing foreign markets of Israel, Australia, Germany and of the EU. We expect our EU-GMP certification to allow Eve to continue to increase sales as these foreign markets mature and expand," said Melinda Rombouts, President and Chief Executive Officer of Eve & Co.

Eve&Co總裁兼首席執行官梅琳達·羅姆布茨(Melinda Romboutts)表示:“我們對Eve&Co團隊的成功和進步以及2021財年第三季度的銷售業績感到非常高興。我們的重點一直放在以色列、澳大利亞、德國和歐盟等新興和不斷增長的海外市場上。我們預計,隨着這些外國市場的成熟和擴張,我們的EU-GMP認證將使Eve能夠繼續增加銷售額。”

Eve & Co has granted an aggregate of 850,000 stock options (each an "Option") to certain directors, officers, and employees of the Company. The Options vest through the passage of time or the achievement of specific goals. The specific goals for the Options vary based upon the duties and responsibility of the recipient. Each Option is exercisable into one common share ("Share") of the Company at a price of $0.14 per Share for a period of five years from the date of grant. All of the Options have been granted pursuant to the Company's Stock Option Plan which has been previously approved by the Company's shareholders and the TSX Venture Exchange.

Eve&Co已向公司的某些董事、高級管理人員和員工授予總計85萬份股票期權(每人一份“期權”)。期權是通過時間的推移或具體目標的實現來實現的。選項的具體目標根據接受者的職責和責任而有所不同。每項購股權可行使為一股本公司普通股(“股份”),價格為每股0.14美元,為期五年,由授出日期起計。所有購股權均根據本公司先前已獲本公司股東及多倫多證券交易所創業板批准的購股權計劃授出。

The financial statements and management discussion and analysis are available on the System for Electronic Document Analysis and Retrieval ("SEDAR") at www.sedar.com and on Eve & Co's website at www.evecannabis.ca.

財務報表以及管理層討論和分析可在電子文件分析和檢索系統(“SEDAR”)www.sedar.com和Eve&Co的網站www.evecannabis.ca上查閲。

ABOUT EVE & CO

關於Eve&CO

Eve & Co Incorporated, through its wholly owned subsidiary Natural MedCo Ltd. ("NMC"), holds cultivation and processing licenses under the Cannabis Act (Canada) for the production and sale of various cannabis products, including dried cannabis, cannabis plants and extraction of cannabis oil and has received EU GMP certification. NMC was Canada's first female-founded licensed producer of medicinal marijuana and received its cultivation license from Health Canada in 2016. Eve & Co is led by a team of agricultural experts and has a licensed 1,000,000 sq. ft. greenhouse located in Strathroy, Ontario.

伊芙公司通過其全資子公司Natural Medco Ltd.(“NMC”)持有種植和加工許可證。大麻法案加拿大)生產和銷售各種大麻產品,包括幹大麻、大麻植物和大麻油提取,並已獲得歐盟GMP認證。NMC是加拿大第一家由女性創立的有執照的醫用大麻生產商,並於2016年從加拿大衞生部獲得種植許可證。Eve&Co由一個農業專家團隊領導,擁有100萬平方米的許可面積。英國“金融時報”温室位於安大略省斯特拉特里。

The Company's website can be visited at www.evecannabis.ca

公司網站網址為:www.evecannabis.ca。

The TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) does not accept responsibility for the adequacy or accuracy of this release.

多倫多證券交易所及其監管服務提供商(該術語在多倫多證券交易所的政策中定義)不對本新聞稿的充分性或準確性承擔責任。

This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur, and include, but are not limited to, the production and sale of bath bombs by the Company, whether sales of bath bombs will occur, if any at all, or recur and the timing thereof. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guaranteeing of future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements and readers should not place undue reliance on such statements. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements, including general business and economic conditions, changes in laws and regulations, product demand, changes in prices of required commodities, competition, the effects of and responses to the COVID-19 pandemic and other risks, uncertainties and factors set out under the heading "Risk Factors" in the Company's management's discussion and analysis dated April 30, 2021 and November 24, 2021 ("MD&A") and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR at www.sedar.com. The Company cautions that the list of risks, uncertainties and other factors described in the MD&A is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. These forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law.

本新聞稿包括含有適用證券法定義的某些“前瞻性信息”的陳述(“前瞻性陳述”)。前瞻性陳述經常使用諸如“計劃”、“繼續”、“預期”、“項目”、“打算”、“相信”、“預期”、“估計”、“可能”、“將”、“潛在”、“建議”等類似詞語,或關於某些事件或條件“可能”或“將”發生的陳述,包括但不限於,公司生產和銷售沐浴炸彈,無論是否會銷售沐浴炸彈,或復發及其時機。儘管公司認為這些前瞻性陳述中表達的預期是基於合理的假設,但這些陳述並不能保證未來的業績,涉及難以控制或預測的風險和不確定因素。因此,實際結果和結果可能與這些前瞻性陳述中表達的大不相同,讀者不應過分依賴這些陳述。前瞻性表述受各種風險、不確定因素和其他因素的影響,管理層認為這些因素在當時的情況下是相關和合理的,可能會導致實際事件、結果、活動水平、業績、前景、機會或成就與前瞻性表述中預測的結果大不相同,這些因素包括一般商業和經濟狀況、法律法規的變化、產品需求、所需商品的價格變化、競爭、新冠肺炎疫情的影響和應對以及其他風險。公司管理層在2021年4月30日和11月24日的討論和分析中“風險因素”標題下列出的不確定因素和因素, 2021年(“MD&A”),並提交給加拿大證券監管機構,可在公司在SEDAR上的發行人簡介中查閲,網址為www.sedar.com。該公司告誡説,MD&A中描述的風險、不確定因素和其他因素並不是詳盡的,其他因素也可能對其結果產生不利影響。請讀者在評估前瞻性陳述時仔細考慮風險、不確定性和假設,並告誡讀者不要過度依賴這些信息。這些前瞻性陳述僅在發表之日發表,公司沒有義務公開更新這些陳述,以反映新的信息或未來事件或情況的發生,除非法律另有要求。

For further information, please contact:

如需更多信息,請聯繫:

Melinda Rombouts
President and Chief Executive Officer
Eve & Co Incorporated
Telephone: (855) 628-6337
 
梅林達·羅伯茨
總裁兼首席執行官
伊芙公司(Eve&Co Inc.)
電話:(855)628-6337

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論